Bayer AG

This committee's technical analysis and 'scoring' of tax legislation directly influence corporate tax structures, R&D credits, and the overall tax burden, which are critical factors for Bayer AG's financial planning and investment decisions.

As the primary committee for taxation, trade, and entitlement spending, it directly impacts Bayer's profitability through corporate tax policy, its global supply chain and market access through trade tariffs, and its healthcare revenue through Medicare pricing.

This committee allocates federal spending, directly determining the budgets for agencies like the FDA, NIH, EPA, USDA, and VA. These funding levels directly affect Bayer's regulatory environment, research opportunities, and government sales.

This committee oversees the Farm Bill, which profoundly impacts the agricultural sector through subsidies, crop insurance, and conservation programs, directly influencing farmers' decisions and the market for Bayer's Crop Science products.

This committee directly regulates the FDA, which is responsible for drug approvals for Bayer's Pharmaceutical and Animal Health products. It also influences NIH research funding and labor laws, all directly impacting Bayer's operations and market performance.

This committee's oversight of antitrust laws and intellectual property is critically important to Bayer AG. Antitrust impacts large mergers (e.g., Monsanto acquisition), and intellectual property (patents) is fundamental to its Pharmaceutical and Crop Science segments.

This committee directly regulates the EPA, which oversees pesticides, herbicides, and other environmental impacts directly relevant to Bayer's Crop Science and chemical/materials segments. It determines regulatory costs for the chemical sector.